Structure Therapeutics (GPCR), which his working on next-gen oral obesity medication, has emerged as the next top M&A target for Big Pharma, Axios’ Katherine Davis reports. The new market for obesity drugs has reshaped dealmaking in biopharma, as big companies look to replace expiring patents and buy into the fast-growing business, the author notes.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GPCR:
- Structure Therapeutics price target raised to $105 from $65 at JPMorgan
- Structure Therapeutics price target raised to $140 from $90 at Guggenheim
- Structure Therapeutics moved to Buy rating at Goldman Sachs
- Novo Nordisk’s renewed M&A appetite sends obesity-drug names higher
- Novo Nordisk says back on the hunt for obesity deals, Bloomberg reports